Clinical trials: Bladder Cancer, completed
Bladder Cancer
Diode Laser Treatment of Bladder Tumors
Laser treatment of pTa low grade bladder tumours in the outpatient department Number of Subjects/Centres Planned: 20 patients will be included in this study.
- Trial name
- NCT02738827
- Testing
- Laser treatment
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Gregers Gautier Hermann
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Transitional Cell Carcinoma of the Bladder
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine
Research Problem: Bladder cancer is one of the major health concerns of the world. The present methods of diagnosis are: Ultra sound, Cystoscopy, CT scan and urine cytology.
- Trial name
- ALA (NCT02101931)
- Testing
- Amino levulinic Acid
- Where
- Saudi Arabia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Princess Al-Johara Al-Ibrahim Cancer Research Center
Superficial Bladder Cancer
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
This study is designed to assess the efficacy and safety of DTA-H19/PEI given as six intravesical instillations of 20 mg of plasmid DNA complexed with PEI into the bladder of patients with intermediate risk superficial bladder…
- Trial name
- NCT00595088
- Testing
- BC-819/PEI
- Where
- 6 sites in United States, Israel
- Volunteers
- 47 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Bladder Cancer, Prostate Cancer
Use of Multiphoton Microscopy in the Diagnosis of Cancer
Multiphoton microscopy (MPM) has been shown to be able to image tissue at a cellular level. Our project will initially evaluated the ability of MPM imaging to distinguish normal bladder urothelium from atypical and malignant…
- Trial name
- MPM (NCT00652210)
- Testing
- Multiphoton microscopy
- Where
- United States
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Laryngeal Masks, Urinary Bladder Neoplasms
Effect of Head Elevation on LMA Insertion
The purpose of this study is to compare the first attempt success rate of laryngeal mask airway insertion according to the degree of head elevation.
- Trial name
- NCT04229862
- Testing
- Laryngeal mask airway insertion
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Superficial Bladder Cancer
Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer
Early single instillation of chemotherapy after TUR is recommended in the European Association of Urology Guidelines. Nevertheless, the procedure is suboptimal for patients with multiple tumors, sometimes is not tolerated and it…
- Trial name
- EMDA/PRE-TUR (NCT01149174)
- Testing
- Mitomycin-C 40 mg
- Where
- Italy
- Volunteers
- 352 people
- Sponsor
- University of Rome Tor Vergata
Bladder Cancer, Breast Cancer
Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors
RATIONALE: Exercise may help improve mobility and relieve fatigue and/or weakness in cancer survivors. It is not yet known whether exercise is more effective than standard therapy in improving mobility and reducing fatigue and/or…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00335491
- Testing
- exercise intervention, complementary or alternative medicine procedure, fatigue assessment and management
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Utah
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Suramin in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have recurrent bladder cancer.
- Trial name
- NCT00006476
- Testing
- suramin, conventional surgery
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cancer Research UK
Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder…
- Conditions
- Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Muscle-invasive Bladder Cancer
- Trial name
- NCT05945108
- Where
- 5 sites in Brazil
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Prostate Cancer, Bladder Cancer
Respiratory Measurement Using Infrared Camera and Respiratory Volume Monitor (ExSpiron 1Xi) for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia
In patients undergoing spinal anesthesia, the investigators used an Infra-red camera and a respiratory volume monitor to determine the accuracy of the ventilation rate of the infra red camera by measuring the respiratory rate…
- Trial name
- NCT02993497
- Testing
- Infrared camera, RVM(Respiratory Volume Monitor)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Yonsei University
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Bladder (Urothelial, Transitional Cell) Cancer, MRI
Bp-MRI Based Multi-planar VI-RADS
This study is a prospective, single-center, observational clinical trial, enrolling 100 patients with malignant bladder tumors admitted to the Department of Urology at the People's Hospital of Jiangsu Province for treatment with…
- Trial name
- NCT06607250
- Testing
- MRI
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Ureteral Neoplasms
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Background: Urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis) often responds initially to standard chemotherapy treatments, but frequently recurs and can often spread to other parts of the body.
- Conditions
- Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral
- Trial name
- NCT01328574
- Testing
- TRC105
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
R115777 in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder…
- Trial name
- NCT00006376
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Screening Tool, Focus Group
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the…
- Trial name
- ACCESS (NCT06412874)
- Testing
- Screening tool
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non Muscle Invasive Bladder Cancer
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
The treatment of non-muscle invasive bladder cancer (NMIBC) is problematic given the variable natural history of the disease. Although contemporary treatment options are limited, new targets and new approaches are under…
- Trial name
- NCT02343614
- Testing
- Celecoxib
- Volunteers
- 58 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Bladder Cancer
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder…
- Trial name
- NCT00047216
- Testing
- tipifarnib
- Where
- 7 sites in United States, Canada
- Sponsor
- University Health Network, Toronto